Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorMichigan State University

About this trial

The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.

Eligibility criteria

Qualifiers

Dominant speakers of North American English

Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)

Present with changes in their speech/voice

Disqualifiers

History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.

Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.

Trial design

Treatments tested in this trial

  • Behavioral speech strategies + speech amplification

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators

Michigan State University

Lead sponsor

National Institute on Deafness and Other Communication Disorders (NIDCD)

Collaborator